Harshwant Grover, MD
Pulmonary Disease · Spokane, WANPI 1639605454
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,320 of the $5,966 with a category attached, or 72.4%. Genentech USA, Inc. accounts for 81.0% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $5,277, more than ten times the $199 reported in 2019.
Across 42 payments — averaging $142.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- Novo Nordisk$125
- Pfizer$115
- AstraZeneca$113
- Actelion Pharmaceuticals US, Inc.$96
- Sanofi-aventis U.S. LLC$95
- plus $590 from 13 others
What the payments were for
- Consulting fees$4,32072%
- Travel & lodging$1492%
- Food & beverage$1,34022%
- Education$1573%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 8 | $4,831 |
| Novo Nordisk | 1 | $125 |
| Pfizer | 1 | $115 |
| AstraZeneca | 6 | $113 |
| Actelion Pharmaceuticals US, Inc. | 3 | $96 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Regeneron Healthcare Solutions, Inc. | 3 | $86 |
| Johnson & Johnson | 1 | $84 |
| United Therapeutics Corporation | 3 | $82 |
| GSK | 4 | $71 |
| Merck | 2 | $60 |
| Abbott | 1 | $49 |
| Sanofi | 2 | $37 |
| Mylan Specialty L.p. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Philips North America LLC | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,966 in reported general payments places this provider in the 85th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $36,632 |
| Spiriva HandihalerTiotropium Bromide | 14 | $10,636 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,896 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $6,148 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $5,059 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $4,073 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,877 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $655 |
| Montelukast Sodium | 18 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta | $71 | $42,77959 claims |
| Boehringer IngelheimSpiriva Respimat | $22 | $6,89611 claims |
| AstraZenecaSymbicort | $113 | $2,87711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Spokane
- Jiten PatelSpokane$200K
- Griffith LiangSpokane$13K
- Fatima AjazSpokane$6K
- Benjamin ArthursSpokane$6K
- Bryan AndersonSpokane$4K
- Jed GordenSeattle$236K
- Dominique PepperOlympia$212K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Nicholas WyshamVancouver$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.